These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28407345)

  • 21. Dosimetric Comparison and Evaluation of 4 Stereotactic Body Radiotherapy Techniques for the Treatment of Prostate Cancer.
    Seppälä J; Suilamo S; Tenhunen M; Sailas L; Virsunen H; Kaleva E; Keyriläinen J
    Technol Cancer Res Treat; 2017 Apr; 16(2):238-245. PubMed ID: 28279147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer.
    Kim DW; Cho LC; Straka C; Christie A; Lotan Y; Pistenmaa D; Kavanagh BD; Nanda A; Kueplian P; Brindle J; Cooley S; Perkins A; Raben D; Xie XJ; Timmerman RD
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(3):509-17. PubMed ID: 24929162
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dosimetric analysis comparing treatment of low-risk prostate cancer with TomoTherapy versus static field intensity modulated radiation therapy.
    Shah AP; Chen SS; Strauss JB; Kirk MC; Coleman JL; Coon AB; Miller C; Dickler A
    Am J Clin Oncol; 2009 Oct; 32(5):460-6. PubMed ID: 19564784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer.
    Chatzikonstantinou G; Keller C; Scherf C; Bathen B; Köhn J; Tselis N
    Brachytherapy; 2021; 20(1):44-49. PubMed ID: 32826171
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel model to correlate hydrogel spacer placement, perirectal space creation, and rectum dosimetry in prostate stereotactic body radiotherapy.
    Hwang ME; Black PJ; Elliston CD; Wolthuis BA; Smith DR; Wu CC; Wenske S; Deutsch I
    Radiat Oncol; 2018 Oct; 13(1):192. PubMed ID: 30285812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity.
    Padmanabhan R; Pinkawa M; Song DY
    Future Oncol; 2017 Dec; 13(29):2697-2708. PubMed ID: 29168659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of Motion-dependent Clinical Outcome of Tumor Tracking Stereotactic Body Radiotherapy for Prostate Cancer.
    Choi HS; Kang KM; Jeong BK; Song JH; Lee YH; Ha IB; Kam SC; Hwa JS; Hyun JS; Do J; Jeong DH; Jeong H
    J Korean Med Sci; 2018 Apr; 33(14):e107. PubMed ID: 29607633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved robotic stereotactic body radiation therapy plan quality and planning efficacy for organ-confined prostate cancer utilizing overlap-volume histogram-driven planning methodology.
    Wu B; Pang D; Lei S; Gatti J; Tong M; McNutt T; Kole T; Dritschilo A; Collins S
    Radiother Oncol; 2014 Aug; 112(2):221-6. PubMed ID: 25108808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosimetric and anatomic indicators of late rectal toxicity after high-dose intensity modulated radiation therapy for prostate cancer.
    Munbodh R; Jackson A; Bauer J; Schmidtlein CR; Zelefsky MJ
    Med Phys; 2008 May; 35(5):2137-50. PubMed ID: 18561689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dosimetric impact of hydrogel spacer use for stereotactic body radiotherapy of localised prostate cancer].
    Ung M; Bossi A; Abbassi L; Vautier J; Anthonipillai V; Chevé M; Blanchard P
    Cancer Radiother; 2021 May; 25(3):237-241. PubMed ID: 33419606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Investigation of Dosimetric Correlates of Acute Toxicity in Prostate Stereotactic Body Radiotherapy: Dose to Urinary Trigone is Associated with Acute Urinary Toxicity.
    Henderson DR; Murray JR; Gulliford SL; Tree AC; Harrington KJ; Van As NJ
    Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):539-547. PubMed ID: 29807801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: non-isocentric CyberKnife versus isocentric RapidArc.
    Lin YW; Lin KH; Ho HW; Lin HM; Lin LC; Lee SP; Chui CS
    Phys Med; 2014 Sep; 30(6):654-61. PubMed ID: 24726212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rectal radiation dose-reduction techniques in prostate cancer: a focus on the rectal spacer.
    Leiker AJ; Desai NB; Folkert MR
    Future Oncol; 2018 Nov; 14(26):2773-2788. PubMed ID: 29939069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative dosimetric analysis of virtual stereotactic body radiotherapy to high-dose-rate monotherapy for intermediate-risk prostate cancer.
    Spratt DE; Scala LM; Folkert M; Voros L; Cohen GN; Happersett L; Katsoulakis E; Zelefsky MJ; Kollmeier MA; Yamada Y
    Brachytherapy; 2013; 12(5):428-33. PubMed ID: 23622710
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy.
    van Lin EN; Hoffmann AL; van Kollenburg P; Leer JW; Visser AG
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):565-76. PubMed ID: 16168848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
    Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
    Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer.
    King CR; Brooks JD; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):877-82. PubMed ID: 21300474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of different contouring definitions of the rectum as organ at risk (OAR) and dose-volume parameters predicting rectal inflammation in radiotherapy of prostate cancer: which definition to use?
    Nitsche M; Brannath W; Brückner M; Wagner D; Kaltenborn A; Temme N; Hermann RM
    Br J Radiol; 2017 Feb; 90(1070):20160370. PubMed ID: 27936891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CT-based online adaptive radiotherapy improves target coverage and organ at risk (OAR) avoidance in stereotactic body radiation therapy (SBRT) for prostate cancer.
    Waters M; Price A; Laugeman E; Henke L; Hugo G; Stowe H; Andruska N; Brenneman R; Hao Y; Green O; Robinson C; Gay H; Michalski J; Baumann BC
    Clin Transl Radiat Oncol; 2024 Jan; 44():100693. PubMed ID: 38021093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.